ATX Stock Overview
A pharmaceutical company, focuses on the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.095 |
| 52 Week High | AU$0.16 |
| 52 Week Low | AU$0.055 |
| Beta | 0.72 |
| 11 Month Change | -26.92% |
| 3 Month Change | 31.94% |
| 1 Year Change | 18.75% |
| 33 Year Change | -53.66% |
| 5 Year Change | 18.75% |
| Change since IPO | -95.25% |
Recent News & Updates
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
Shareholder Returns
| ATX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -20.8% | -1.4% | -1.3% |
| 1Y | 18.8% | 13.5% | 11.0% |
Return vs Industry: ATX exceeded the Australian Biotechs industry which returned 13.5% over the past year.
Return vs Market: ATX exceeded the Australian Market which returned 11% over the past year.
Price Volatility
| ATX volatility | |
|---|---|
| ATX Average Weekly Movement | 25.2% |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ATX's share price has been volatile over the past 3 months.
Volatility Over Time: ATX's weekly volatility has increased from 15% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a pharmaceutical company, focuses on the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline includes AMP945, an inhibitor of FAK that has completed Phase I clinical trial for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases; and AMP886 for treating acute myeloid leukemia and various solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018.
Amplia Therapeutics Limited Fundamentals Summary
| ATX fundamental statistics | |
|---|---|
| Market cap | AU$26.11m |
| Earnings (TTM) | -AU$4.50m |
| Revenue (TTM) | AU$4.45m |
5.9x
P/S Ratio-5.8x
P/E RatioIs ATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATX income statement (TTM) | |
|---|---|
| Revenue | AU$4.45m |
| Cost of Revenue | AU$441.99k |
| Gross Profit | AU$4.01m |
| Other Expenses | AU$8.51m |
| Earnings | -AU$4.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 90.07% |
| Net Profit Margin | -101.14% |
| Debt/Equity Ratio | 13.1% |
How did ATX perform over the long term?
See historical performance and comparison